MB Clinical Research

06/05/2026

https://icont.ac/51iy9

Although low-density lipoprotein cholesterol (LDL-C) is the primary lipoprotein risk marker used to assess an individual’s risk of atherosclerotic cardiovascular disease (ASCVD), both non-high-density lipoprotein cholesterol (non-HDL-C; representing the cholesterol in all atherogenic lipoproteins)...

03/23/2026

https://icont.ac/51fyV

Just as this edition of our newsletter was going to press, the 2026 American College of Cardiology/American Heart Association/Multi-society Guideline on the Management of Dyslipidemia was released (click here to view). The Guideline was simultaneously published online by Circulation and the Journal....

09/15/2025

https://icont.ac/517nV

2025 Focused Update of the ESC/EAS Guidelines for the Management of Dyslipidemias Since the release of the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Guidelines for the Management of Dyslipidemias, several new randomized controlled trials related to dyslipidemia...

06/16/2025

Volume 9 Issue 2 of the MB Clinical Research Newsletter posted below

https://icont.ac/513Lt

03/24/2025

Volume 9 issue 1 of the MB Clinical Research Newsletter is posted below:

https://icont.ac/50ZSQ

12/03/2024

Volume 8 issue 4 of the MB Clinical Research Newsletter posted below:

https://icont.ac/50UtN

09/23/2024

https://icont.ac/50hZ8
Volume 8 issue 3 of the MB Clinical Research Newsletter posted below:

Intensive low-density lipoprotein cholesterol (LDL-C) lowering with proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors added to statin therapy has been shown to substantially reduce atherosclerotic cardiovascular disease (ASCVD) events.1-3 Furthermore, results from the Effects of the P...

07/01/2024

Volume 8 issue 2 of the MB Clinical Research Newsletter posted below:
https://icont.ac/4Z7Yt

03/21/2024

Volume 8 issue 1 of the MB Clinical Research Newsletter posted below:
https://icont.ac/4XfcF